Serum thymidine kinase activity as a "real-time" clinical biomarker of tumor response to CDK4/6 inhibition in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer

被引：0
|
作者：
Bagegni, Nusayba
Williams, Amy
Grigsby, Isabella
Bergqvist, Mattias
Clifton, Katherine
Ma, Cynthia
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-15-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-15-06
引用
收藏
页数：3
相关论文
共 50 条
  • [31] COMPARISON BETWEEN EVEROLIMUS (AFINITOR®) AND CHEMOTHERAPY AGENTS (CAPECITABINE, DOCETAXEL AND DOXORUBICIN) FOR THE TREATMENT OF HORMONE RECEPTOR POSITIVE (HR+) HER2 NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER
    Vieira, J.
    Chandiwana, D.
    Taylor, M.
    Lewis, L.
    VALUE IN HEALTH, 2013, 16 (07) : A396 - A396
  • [32] Copy loss enrichment at metastatic disease progression in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibition
    Davis, A. A.
    Luo, J.
    Zheng, T.
    Dai, C.
    Suresh, R.
    Ademuyiwa, F. O.
    Rigden, C.
    Clifton, K.
    Weilbaecher, K.
    Frith, A. E.
    Tandra, P.
    Summa, T.
    Thomas, S.
    Peterson, L.
    Wang, X.
    Du, P.
    Jia, S.
    King, B. L.
    Krishnamurthy, J.
    Ma, C. X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S587 - S588
  • [33] The Effects of HER2 on CDK4/6 Activity in Breast Cancer
    Sinclair, William D.
    Cui, Xiaoyan
    CLINICAL BREAST CANCER, 2022, 22 (03) : E278 - E285
  • [34] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [35] HR+/HER2-metastatic Breast Cancer Increasing Data Density of CDK4/6 Inhibitors
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 485 - 485
  • [36] Disease features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients
    Wang, Jinhao
    Liu, Yaxin
    Shao, Bin
    Dong, Hang
    Zheng, Tiantian
    Du, Pan
    Jia, Shidong
    King, Bonnie
    Wang, Jing
    Liu, Xiaoran
    Li, Huiping
    CANCER RESEARCH, 2023, 83 (05)
  • [37] A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i)
    Mainor, Candace Bavette
    Barrows, Elizabeth Dominic
    Wang, Hongkun
    Lynce, Filipa
    Ashai, Nadia
    Collins, Julie Marie
    Swanson, Nicole
    Castle, Julie
    Novielli, Antonella
    Slingerland, Joyce
    Isaacs, Claudine
    Pohlmann, Paula R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
    Aapro, Matti
    De Laurentiis, Michelino
    Rea, Dan
    Bargallo Rocha, Juan Enrique
    Elizalde, Roberto
    Landherr, Laszlo
    Linderholm, Barbro
    Mamounas, Eleftherios
    Markopoulos, Christos
    Neven, Patrick
    Petrovsky, Alexander
    Rouzier, Roman
    Smit, Vincent
    Svedman, Christer
    Schneider, Daniel
    Thomssen, Christoph
    Martin, Miguel
    BREAST, 2017, 33 : 191 - 199
  • [39] First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC)
    Hoskins, Kent F.
    Richards, Paul
    Wisinski, Kari
    CANCER RESEARCH, 2018, 78 (13)
  • [40] Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
    Engel-Nitz, Nicole M.
    Johnson, Mary G.
    Johnson, Michael P.
    Cha-Silva, Ashley S.
    Kurosky, Samantha K.
    Liu, Xianchen
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 1049 - 1062
12345